Tani, Yasuhiro
Ishihara, Ryu
Inoue, Takahiro
Okubo, Yuki
Kawakami, Yushi
Matsueda, Katsunori
Miyake, Muneaki
Yoshii, Shunsuke
Shichijo, Satoki
Kanesaka, Takashi
Yamamoto, Sachiko
Takeuchi, Yoji
Higashino, Koji
Uedo, Noriya
Michida, Tomoki
Kato, Yusuke
Tada, Tomohiro
Article History
Received: 22 December 2022
Accepted: 26 April 2023
First Online: 25 May 2023
Declarations
:
: This study was approved by the Certified Review Board of Osaka International Cancer Institute (no. 19221-3) and registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs052200015 on 18/05/2020. This study was performed in accordance with the Declaration of Helsinki and written informed consent was obtained from all participants.
: Not applicable.
: Satoki Shichijo has received personal fees from Olympus Corporation, Daiichi-Sankyo, EA Pharma, AstraZeneca, AI Medical Service Inc., and Jannsen Pharmaceutical. Takashi Kanesaka has received personal fees from Olympus Corporation. Yoji Takeuchi has received personal fees from Olympus Corporation, Boston Scientific Japan, FUJIFILM Medical Co., Ltd, Daiichi-Sankyo, Miyarisan Pharmaceutical, Asuka Pharmaceutical, AstraZeneca, EA Pharma, Zeria Pharmaceutical, Fujifilm, Kaneka Medix, and Kyorin Pharmaceutical. Noriya Uedo has received personal fees from Olympus Corporation, Boston Scientific Japan, FUJIFILM Medical Co., Ltd, Daiichi-Sankyo, Takeda Pharmaceutical, EA Pharma, Otsuka Pharmaceutical, AstraZeneca, AI Medical Service Inc., and Miyarisan Pharmaceutical. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd, Daiichi-Sankyo, Ono Pharmaceutical, EA Pharma, and AstraZeneca. Tomohiro Tada is a shareholder in AI Medical Service Inc. and holds the following patent PCT/JPT2018/040381. The other authors have no financial relationships to disclose.